Steve Brozak
Stock Analyst at WBB Securities
(2.72)
# 1,947
Out of 5,182 analysts
9
Total ratings
50%
Success rate
50.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $14.67 | +206.75% | 3 | Oct 15, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.04 | +476.92% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.42 | +780.28% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.04 | +1,538,361.54% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $14.67
Upside: +206.75%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.04
Upside: +476.92%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.42
Upside: +780.28%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.04
Upside: +1,538,361.54%